Researchers are reporting early success with a novel HIV treatment approach that could suppress the virus for years using a single infusion, according to a study presented this week. The therapy represents an adaptation of gene-editing technology already proven effective against blood cancers.
The study involved a small group of patients who received an infusion designed to modify their immune cells to resist HIV infection. Rather than requiring daily medication, this one-time treatment appears to offer durable viral suppression, meaning patients may go years without needing additional interventions.
The approach builds on CRISPR gene-editing techniques and CAR-T cell therapy, methods that have already transformed treatment for certain leukemias and lymphomas. Researchers essentially remove immune cells from HIV-positive patients, engineer them in the laboratory to resist the virus, then reintroduce the modified cells into the body.
The preliminary results show that modified cells persisted and continued functioning months after infusion, with some patients maintaining undetectable viral loads without antiretroviral drugs. This differs fundamentally from current HIV treatment, which typically requires lifelong daily medication to keep the virus suppressed.
While the findings are promising, the sample size remains small, and longer follow-up data will determine whether viral suppression truly lasts for years as suggested. Researchers must also evaluate whether the therapy works equally well across diverse patient populations and HIV subtypes.
This approach complements rather than replaces existing treatments. Current antiretroviral therapy has transformed HIV into a manageable chronic condition for millions, though adherence challenges and drug resistance remain issues for some patients. A long-acting infusion could address these barriers for people who struggle with daily pill regimens or face medication access problems.
The research team hopes to expand trials in coming years. If sustained suppression proves durable in larger patient groups, this therapy could offer HIV-positive individuals a radically different treatment option that requires minimal ongoing medical